OHDSI APAC State of Community 2022

Mui Van Zandt
VP/GM, Real World Data & Technology, IQVIA
OHDSI APAC Leader
Journey of OHDSI Korea

2014
Korea joins OHDSI
Prof Park (Ajou Uni.) showed the first public Achilles webpage at the 1st OHDSI Face-to-Face meeting

2017
1st OHDSI Korea International Symposium

2018
Launch of FEEDER-NET project

2019
OHDSI Korea Datathon

2019
Translation of ‘The Book of OHDSI’

2019
OHDSI Korean Tutorial

2019
OHDSI Korea International Symposium 2019
**Journey of OHDSI China**

- **First Hackathon**
  - Shanghai
  - 85 participants
  - May 2017

- **Zhi Jiang University**
  - Hangzhou
  - 30 participants
  - June 2017

- **Beijing Hackathon**
  - Xi’an
  - 80 participants
  - Oct 2017

- **China Symposium**
  - Shanghai
  - 200 participants
  - June 2018

- **China Symposium**
  - Guangzhou
  - 180 participants
  - June 2018

- **Beijing Hackathon**
  - Beijing
  - 50 participants
  - Dec 2018

- **China Symposium**
  - Shanghai
  - 200 participants
  - June 2019

- **China Symposium**
  - Guangzhou
  - 180 participants
  - Aug 2019

- **Beijing Hackathon**
  - Xi’an
  - 80 participants
  - Oct 2019

- **Fudan Study-a-thon**
  - Shanghai
  - 80 participants
  - Aug 2019

- **Tutorial**
  - Guangzhou
  - 60 Participants
  - Oct 2019
OHDSI APAC
Formation
Our journey begins

1st APAC Symposium
110+ Attendees

1st APAC Tutorial
- CDM & Vocabulary
- Data Quality
- OMOP Ecosystem

2 x APAC Studies
- CORAZON study
  Comparative effectiveness and safety of direct oral anticoagulants in patients with atrial fibrillation.
- LEGEND study
  Comparative effectiveness and safety of second-line antihypertensive agents

https://www.ohdsi.org/events/2020-apac-ohdsi-symposium/?_ga=2.253239753.1500976604.1667796417-337476248.1642645249
Training Technical Expertise

1st APAC ETL Workshop

Day 1 (Aug 12)

- Introduction to ETL
- Agile methodology
- Source Data Analysis
- Vocabulary Mapping
- ETL Specification Writing

Day 2 (Aug 13)

- Common issues in ETL Conversion
- OMOP ETL Development
- Data Quality Checks
Bridging the gap across APAC

- Sept. 23, 2021 - Introducing The OHDSI Center at the Roux Institute
- Sept. 9, 2021 - Workgroup Updates (Oncology, Psychiatry, UK Biobank/Registry, EHR)
- August 26, 2021 - Network Studies
- August 12, 2021 - Global Symposium Preview
- July 29, 2021 - EUMAEUS (Evaluating Use of Methods for Adverse Event Under Surveillance)
- July 15, 2021 - Introduction to the OMOP Oncology Module / How To Do A Network Study
- July 1, 2021 - Regional Updates / Mid-Year Review
- June 17, 2021 - OMOP Project: Applying the OMOP CDM to Hepatobiliary Clinical Research Database at Zhongshan
- June 3, 2021 - APAC Network Research
- May 22, 2021 - 10-Minute Tutorials
- May 8, 2021 - Collaborator Presentations
- April 22, 2021 - Regional Updates
- April 8, 2021 - OMOP Projects (Presentations by Yuan Lu and Namki Hong)
- Mar. 25, 2021 - OHDSI APAC Network Research (Presentation by Lei Feng)
- Mar. 11, 2021 - Collaborator Showcase (Presentations by Ty Stanford and Jason Hsu)
- Feb. 25, 2021 - Welcome To The Journey (Helping Our OHDSI Newcomers Get Started)
- Jan. 28, 2021 - APAC Community Kickoff Call
Research Initiatives

*Seng Chan You*
Characterization of Health by OHDSI AP chapter to identify Temporal Effect of the Pandemic (CHAPTER)

*Celine Chui and team*
Comparison of mortality, morbidities & healthcare resources utilisation between patients with and without a diagnosis of COVID-19

*Nicole Pratt*
Treatment, utilisation and safety of medicines for Multiple Sclerosis (TELEMUS)

*Chungsoo Kim*
Data quality of OHDSI APAC: CDM Inspection study
**Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort**

Hai Lin, MD, Nui Van Zandt, US, Lin Li, MD, Jun Wang, MD, Yong Chen, MD, Zhang Yan, MD, Lijun Jiang, MD, Mingming Zhu, MD, Xiang Yang, MD, and Jinhua Chen, MD.

**Abstract**

**IMPORTANCE** More than 1 billion adults have hypertension globally, and 70% cannot achieve their hypertension control goal with monotherapy alone. Data are lacking on clinical use of patients with dual combination therapies prescribed to patients who escalate from monotherapy.

**OBJECTIVE** To investigate the most common dual combination therapies prescribed for treatment escalation in different countries and the treatment use by age, sex, and history of cardiovascular disease.

**DESIGN, SETTING, AND PARTICIPANTS** The cohort study used data from the electronic health record databases that cover 188 million patients across 7 countries between January 2000 and December 2019. Included participants were adult patients ages ≥18 years who were newly initiated antihypertensive dual combination therapy after escalating from monotherapy. There were 3 databases included for 3 countries: the Korea Longitudinal Patient Dataset (KLPD), Australia and Electronic Health Records-Based Research Network (Australia EHR) from Australia, Aizu University Hospital (AUSDB) from Japan, and Kyung Hee University Hospital (KHUH) from South Korea. The joint Longitudinal Health Insurance Database (JLHID) from Singapore and Chonbuk National University Hospital (CHUNH) databases from South Korea, and Kazo Tohoku Hospital (KTH) and National University Hospital (NUH) databases from Singapore. Data were analyzed from June 2020 through August 2021.

**EXPOSURES** Treatment with dual combination of the 4 most commonly used antihypertensive drug classes: angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), diuretics, and/or thiazide-like diuretics.

**KEY POINTS**

**Questions:** What are the most common antihypertensive dual combinations prescribed to patients who escalate from monotherapy in clinical practice, and how do the combinations differ by country and patient demographic subgroup?

**Findings:** In this cohort study of 630,335 individuals from 11 large databases, dual combinations of antihypertensive drug classes were commonly used, with large variation across countries and demographic groups.

**Meaning:** These findings on the diversity of antihypertensive used in practice suggest that future research is needed to investigate what medication combinations are associated with best outcomes for whom patients.

---

**Annals of Internal Medicine**

**Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation**

Wallis C.Y. Lau, PhD; Carmen Olga Torre, MS; Kenneth K.C. Man, PhD; Henry Morgan Stewart, PhD; Sarah Seeger, BA; Mul Van Zandt, BSc; Christian Reich, MD; Jing Li, MS; Jack Brewster, PhD; Gregory Y.H. Lip, MD; Aroon D. Hingorani, PhD; Li Wei, PhD; and Ian C.K. Wong, PhD.

**Background:** Current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to guide the choice of DOAC.

**Objective:** To do a large-scale comparison between all DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) in routine clinical practice.

**Design:** Multinational population-based cohort study.

**Setting:** Five standardized electronic health care databases, which covered 221 million people in France, Germany, the United Kingdom, and the United States.

**Participants:** Patients who were newly diagnosed with AF from 2010 through 2019 and received a new DOAC prescription.

**Measurements:** database-specific hazard ratios (HRs) of ischemic stroke or systemic embolism, intracranial hemorrhage (ICH), gastrointestinal bleeding (GIB), and all-cause mortality between DOACs were estimated using a Cox regression model stratified by propensity score and pooled using a random-effects model.

**Conclusion:** Among patients with AF, apixaban use was associated with lower risk for GIB and similar rates of ischemic stroke or systemic embolism, ICH, and all-cause mortality compared with dabigatran, edoxaban, and rivaroxaban. This finding was consistent for patients aged 80 years or older and those with chronic kidney disease, who are often underrepresented in clinical trials.

**Primary Funding Source:** None.
Welcome!

- South Korea (2014)
- China (2016)
- Japan (2019)
- Australia (2019)
- Singapore (2020)
- Taiwan (2020)

INDIA (2022)
1st In-person APAC Symposium

2022 OHDSI APAC 亞太年會在北醫

2021台灣正式成為OHDSI亞洲第六國分部

並爭取到2022亞洲年會在台北的主辦權

讓我們一起用健康資料軟實力在世界舞台發光發熱！

現正熱烈報名中！！！
OHDSI Book Localization
## Atlas Localization

- **ATLAS Localization**
  - Available in Korean and Chinese since 2020
The Journey Continues…

• Tutorials in local languages
• Working group collaboration
  – Education working group
  – Glossary of terms localization
Thank you!